TABLE OF CONTENTS
Chapter 1: Executive Summary
- Scope of this Report
- Summary of Findings in this Report
- Market Segmentation of the Model Organisms Space: Why Model Organisms and Where Do They Fit in Drug Discovery and Development?
- Model Organisms and the Various Disease Areas Where they are Currently Being Deployed
- Overview of the Competitive Landscape
- Opportunities in the Model Organisms Space and Direction of the Field
Chapter 2: Current and Emerging Model Organisms in Drug
- Discovery and Development
- Scope of this Chapter
- Introduction
- The Various Model Organisms Deployed in Drug Discovery and Development
- Caenorhabditis elegans (C. elegans)
- Zebra.sh (Danio rerio)
- Diseases where Zebra.sh have had Impact as a Model System
- Cancer Biology and Apoptosis
- The Mouse (Mus musculus or Mus spretus)
- The Rat
- The Fruit Fly (Drosophila melanogaster)
- Summary
- Comparisons Across the Model Organisms Landscape: Current and Emerging Model Organisms
- Relevant Scienti.c Literature References in the Model Organisms Space Cited in this Chapter
Chapter 3: Market Opportunity in the Model Organisms Space
- Scope of this Chapter
- Proprietary End-user Survey Administered by D&MD
- Quantitative Market Parameters
- Qualitative Factors Affecting the Model Organisms Marketplace
- What technology and market trends in the model organisms space
- Drug discovery and development segments in which animal models are
- being deployed and are they growing or declining:
- Key technologies used in conjunction with animal models
- Novel and emerging animal models for pharmaceutical R&D:
- Unmet needs in the pharmaceutical R&D space:
- Current Technology and Market Trends in Model Organisms for Drug Discovery and
- Development
- Intellectual Property (Patent) Volume and Trends in the Model Organisms Space
- Quantitative Market Modeling of the Model Organisms Space
- Strategic Analysis and Trends in the Model Organisms Space
Chapter 4: Deploying Model Organisms in Drug Discovery and Development Presentation
Chapter 5: Company Pro.les
- AVEO Pharmaceuticals, Inc.
- BioMarker Pharmaceuticals, Inc.
- Cambria Biosciences
- Chronogen
- Danio Labs
- Devgen
- Discovery Genomics
- Exelixis
- ARTEMIS Pharmaceuticals GmbH
- Ingenium Pharmaceuticals AG
- Lexicon Genetics Inc.
- Phenomix
- Phylonix Pharmaceuticals, Inc.
- Union Biometrica
- Xenogen
- Zygogen, LLC
TABLE OF EXHIBITS
- Exhibit 1.1 Business Models in the Model Organisms Space
- Exhibit 1.2 Various Model Organisms and the Disease Areas Where They Are Deployed Currently
- Exhibit 1.3 Summary of the Competitive Landscape in the Model Organisms Space
- Exhibit 2.1 Advantages of the Zebra.sh over the Mouse as a Model System to Study Human Diseases
- Exhibit 2.2 Comparative Analysis of the Model Organisms Space (Features and Bene.ts)
- Exhibit 3.1 Key Challenges in the Deployment of Model Organisms in Drug Discovery
- Exhibit 3.2 The Top Drivers in the Model Organisms Marketplace
- Exhibit 3.3 Total Screening in the Pharmaceutical Industry Performed Using Animal Models
- Exhibit 3.4 Expectation of Growth/Decline in Cost Per Data Point Allocated to Model Organisms
- Exhibit 3.5 The Market Landscape and its Expected Evolution in the Model Organisms Space
- Exhibit 3.6 Model Organisms Patents Distributed by Year of Filing
- Exhibit 3.7 Assignees of Model Organism Patents
- Exhibit 3.8 Model Organism Patents Grouped by Assignee Country
- Exhibit 3.9 Business Model of Companies in the Model Organisms Space
- Exhibit 3.10 Adoption Curve: Model Organisms Marketplace with Time
- Exhibit 3.11 No Clear Winner Yet in the Model Organisms Space: Market Opportunity Exists for New Entrants
|
Related Report
|
View Cart
